Investorideas.com

Get great ideas from our AI, cannabis, cleantech, crypto, esports and mining podcasts - be a guest or sponsor : 800 665 0411


Share on StockTwits

AI Eye Episode 417: Nuance (NasdaqGS: $NUAN) Announces Strategic Collaboration with MITRE and Cancer Genetics (NasdaqCM: CGIX) Enters Definitive Merger with StemoniX

 

Point Roberts, WA and Vancouver, BC - August 24, 2020 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and advancements in artificial intelligence.

Listen to today's podcast:

https://www.investorideas.com/Audio/Podcasts/2020/082420-AI-Eye.mp3

AI Eye Episode 417: Nuance (NasdaqGS: $NUAN) Announces Strategic Collaboration with MITRE and Cancer Genetics (NasdaqCM: CGIX) Enters Definitive Merger with StemoniX

SHARE PODCAST:

Hear the AI Eye on Spotify

Today's Column - The AI Eye - Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (NasdaqGS:NUAN) (NasdaqCM:CGIX)

Nuance Communications, Inc. (NasdaqGS:NUAN) has announced a strategic collaboration with not-for-profit R&D organization MITRE to "advance the mCODE™ (minimal Common Oncology Data Elements) data standard for improved cancer research and treatment using the AI-powered Nuance® Dragon Medical One solution." Diana Nole, Nuance Communications, executive vice president and general manager of healthcare, explained:

"Collecting clinical data specific to oncology treatment has traditionally been a difficult task to overcome. Combining Nuance's AI expertise with the mCODE data standard provides oncologists with the ability to easily collect and gain access to critical outcome data by simply using their voice to securely dictate notes and search within the EHR using Nuance Dragon Medical One. This will garner significant advancements in data collection, which will, in turn, dramatically improve patient treatment and care."

Cancer Genetics, Inc. (NasdaqCM:CGIX) announced the entry into a definitive merger agreement with StemoniX, Inc., the latter of which is described as "a leader in developing high-throughput disease-specific human organoid platforms integrated with leading-edge data science technologies." The terms of the merger agreement indicate that StemoniX will retain its name and merge with a newly formed subsidiary of Cancer Genetics. Jay Roberts, Cancer Genetics CEO, explained:

"The process of discovering and developing a new drug candidate takes years and comes with a price tag of hundreds of millions - or even billions - of dollars. However, we are at unique time in the drug discovery industry as the convergence of technological innovations in both biology and software will transform conventional workflows in time and accuracy. To convert the time-consuming and labor-intensive process of developing a drug for market, we now look to supplement traditional discovery and drug approval mechanisms to include humanized cell-based assays with artificial intelligence (AI) along with our core vivoPharm business. Given that our strategy and approach are strongly aligned with those of StemoniX, we are pleased to have moved forward with this proposed transaction."

Global AI in Diagnostics Market to Reach $1.3 Billion by 2026

Research from ReportLinker finds that the global AI in Diagnostics market will reach $1.3 billion by 2026 with a compound annual growth rate (CAGR) of 27.4 percent in the forecast period 2020-2026. An outline from the report's summary reads:

Artificial intelligence in healthcare is one of the most important scientific advancements in medicine so far. The participation of several start-ups in the development of AI-driven imaging and diagnostic solutions is a key factor contributing to the growth of the sector.

Artificial intelligence applications vary from image acquisition, processing to aided reporting, follow-up, data storage, data mining, etc. The report provides a balance between threats to AI and opportunities for radiologists in the modern medical world. The use of machine learning combines computational models and algorithms that replicate the brain's biological neural network architecture, i.e., artificial neural networks (ANNs). Output wise, Deep learning has a higher rate of success relative to conventional machine learning.

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here or become an Investor Ideas member

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye - Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android

Contact Investorideas.com

800 665 0411



Get more tech stocks investor ideas - news, articles, podcasts and stock directories

Buy a technology guest post on Investorideas.com